Compare NXTC & CVV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXTC | CVV |
|---|---|---|
| Founded | 2015 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8M | 27.9M |
| IPO Year | 2019 | 2007 |
| Metric | NXTC | CVV |
|---|---|---|
| Price | $6.83 | $4.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 51.7K | ★ 54.6K |
| Earning Date | 11-10-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.86 |
| EPS | N/A | ★ 1.36 |
| Revenue | $22,378,000.00 | ★ $41,128,639.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.35 |
| Revenue Growth | N/A | ★ 96.27 |
| 52 Week Low | $1.55 | $2.96 |
| 52 Week High | $15.74 | $9.10 |
| Indicator | NXTC | CVV |
|---|---|---|
| Relative Strength Index (RSI) | 54.35 | 60.15 |
| Support Level | $4.28 | $3.65 |
| Resistance Level | $6.66 | $4.97 |
| Average True Range (ATR) | 0.80 | 0.24 |
| MACD | 0.09 | 0.12 |
| Stochastic Oscillator | 69.35 | 89.78 |
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
CVD Equipment Corp designs, develops, and manufactures a broad range of equipment used to develop and produce materials and coatings for the aerospace, compound semiconductor, semiconductor, aerospace, battery energy storage markets as well as industrial applications, and research. It currently conducts its business through two reportable segments: CVD Equipment, which designs and manufactures chemical vapor deposition, physical vapor transport and thermal process equipment; and SDC, which designs and manufactures ultra-high purity gas and chemical delivery control systems. Its target markets are aerospace & defense and industrial, microelectronics / high power electronics, and EV battery materials / energy storage.